KRAS in NSCLC: Beyond G12C
Podcast | English | 2024 | 46 Min
Image For Activity Cover
No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, focusing on non-G12C mutations. KRAS mutations are very common in lung cancer and while there are now multiple approved and active KRAS inhibitors, they are specifically for the G12C mutation. Newer strategies are needed for other common mutations, such as KRAS G12V and G12D, and fortunately, new drugs are on the horizon.

Podcast Hosts:
  • Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA 

Podcast Guests: 

  • Mariana Brandao, MD, Medical Oncologist, Institut Jules Bordet, University of Brussels, Belgium
  • Rajwanth Veluswamy, MD, Associate Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY,USA
Powered By